Sanofi (NASDAQ: SNY) reported third‑quarter and first‑nine‑month 2026 financial results, with Q3 net revenue of EUR 14.444 billion (approx. USD 16.62 billion), up 14.3% year‑on‑year at constant exchange rates (CER), driven by new product launches and flagship immunology franchise Dupixent (dupilumab). Net revenue for the first nine months reached EUR 36.550 billion (approx. USD 42.07 billion), a 15.2% year‑on‑year increase.
Financial Milestone
| Item | Q3 2026 | 9M 2026 |
|---|---|---|
| Net Revenue (Total) | EUR 14.444 bn (+14.3% CER) | EUR 36.550 bn (+15.2% CER) |
| United States | EUR 8.603 bn (+23.9%) | EUR 20.236 bn (+27.4%) |
| Europe | EUR 2.579 bn (−0.9%) | EUR 6.883 bn (+1.9%) |
| China | EUR 762 mn (+2.6%) | EUR 2.087 bn (−1.5%) |
- U.S. Growth Drivers: Immunology products (Dupixent, Kevzara), newly launched medicines, and insulins; vaccines declined 6.8% on lower influenza vaccine and Beyfortus (nirsevimab) sales.
- Europe: A slight decline caused by drops in influenza vaccines and established medicines.
- Rest of World: Propelled by Dupixent and newly launched products.
Core Product Performance
| Product | Q3 2026 Sales | YoY Growth (CER) | Highlights |
|---|---|---|---|
| Dupixent (dupilumab) | EUR 5.687 bn | +34.8% | Second consecutive quarter above EUR 5 bn; 9M sales EUR 15.011 bn (+34.5%); U.S. +40.2%; Rest of World +22.6% led by Japan, Canada, Brazil, China |
| Newly Launched Portfolio | EUR 1.390 bn | +31.4% | 9M sales EUR 3.866 bn (+42.3%); ALTUVIIIO EUR 408 mn (+37.8%), Ayvakit EUR 203 mn (+46.0%), Rezurock EUR 165 mn (+43.0%) |
| Kevzara (sarilumab) | EUR 222 mn | +67.9% | Substantial immunology growth |
| Vaccines | EUR 3.185 bn | −6.6% | Northern Hemisphere influenza delivery phase‑shifting; U.S. Beyfortus −39.3%; polio/pertussis/Hib (incl. Heplisav‑B) +24.9% |
| Lantus (insulin glargine) | EUR 530 mn | +18.5% | U.S. net price improvements and share expansion |
| Toujeo | EUR 430 mn | +31.2% | U.S. net price improvements and share expansion |
China Market – Steady Growth Amid Intensive New Product Launches
- Q3 Performance: Revenue of EUR 762 million (approx. USD 880 million), up 2.6% at CER, largely in line with overall market growth; 9M revenue of EUR 2.087 billion, down 1.5% year‑on‑year.
- Growth Drivers: Sarclisa (isatuximab), Dupixent, and insulins; the vaccine business saw lower polio/pertussis/Hib combination vaccine sales due to declining birth rates.
- 2026 Launch Momentum: Successive China rollouts of Aplezure (afamelanotide), Axuro (roflumilast), and Rystiggo (rozanolixizumab).
- Regulatory Catalyst: China’s National Medical Products Administration (NMPA) has accepted and granted Priority Review to Beyfortus (nirsevimab) for a second RSV season indication in children up to 2 years of age.
Market Impact & Outlook
- Immunology Franchise Strength: Dupixent’s second straight quarter above EUR 5 billion – with U.S. growth of +40.2% – confirms its position as one of the world’s largest specialty pharmaceutical brands and Sanofi’s core earnings engine.
- Launch Portfolio Scaling: New launches grew +42.3% over nine months to EUR 3.866 billion, accelerating the company’s transition away from legacy established products.
- Vaccine Headwinds Transitory: The Q3 vaccine decline reflects timing shifts in Northern Hemisphere influenza deliveries and a tougher Beyfortus comparison rather than structural demand erosion; polio/pertussis/Hib momentum (+24.9%) partially offsets.
- U.S. Diabetes Recovery: Double‑digit gains in Lantus (+18.5%) and Toujeo (+31.2%) signal successful net‑price strategy and share recapture in insulin.
- China Optionality: Steady Q3 growth (+2.6%), an aggressive 2026 launch cadence, and NMPA Priority Review for the Beyfortus second‑season label position China for re‑acceleration once launch contributions scale.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Sanofi’s product launches, regulatory reviews, vaccine delivery timing, and commercial performance expectations. Actual results may differ materially due to risks including currency fluctuations, regulatory outcomes, competitive dynamics, immunization demand, and market conditions in the United States, Europe, and China. Figures are as reported in the company’s Q3 2026 disclosure; growth rates are at constant exchange rates (CER) unless otherwise noted.-Fineline Info & Tech
